仑伐替尼联合周疗紫杉醇治疗复发性子宫内膜癌和卵巢癌的I期研究
该I期研究采用3+3设计,评估仑伐替尼联合周疗紫杉醇在复发性子宫内膜癌和铂耐药上皮性卵巢癌患者中的最大耐受剂量和毒性。共入组26例患者,确定MTD为仑伐替尼16mg联合紫杉醇80mg/m2。
要点
- MTD为仑伐替尼16mg每日联合紫杉醇80mg/m2每周。
- 客观缓解率65%,卵巢癌71%,子宫内膜癌50%。
- 中位PFS 12.4个月,子宫内膜癌14.0个月,卵巢癌7.2个月。
核心结论
- 仑伐替尼联合周疗紫杉醇方案耐受性良好,在子宫内膜癌和卵巢癌中观察到令人鼓舞的抗肿瘤活性,值得进一步开发。
研究设计与样本
- I期临床试验,采用3+3剂量递增设计,入组26例复发性子宫内膜癌或铂耐药上皮性卵巢癌患者。
- 紫杉醇80mg/m2静脉注射第1、8、15天,仑伐替尼每日口服,28天为一周期。
- 仑伐替尼剂量水平为8mg、12mg、16mg、20mg。
- 毒性采用CTCAE v4.03记录,疗效采用RECIST 1.1标准评估。
主要发现
- 最大耐受剂量为仑伐替尼16mg联合紫杉醇80mg/m2。
- 发生率≥25%的任何级别毒性包括贫血、中性粒细胞减少、淋巴细胞减少、黏膜炎、恶心、腹泻、厌食、高血压、疲乏、蛋白尿、鼻出血、声音嘶哑。
- 客观缓解率65%,其中卵巢癌71%,子宫内膜癌50%。
- 中位无进展生存期12.4个月,子宫内膜癌14.0个月,卵巢癌7.2个月;54%的患者PFS>6个月。
关键数值与推荐
- 最大耐受剂量:仑伐替尼16mg每日联合紫杉醇80mg/m2每周。
临床怎么用
- 该联合方案在复发性子宫内膜癌和铂耐药卵巢癌中显示出可管理的毒性和鼓舞人心的疗效,可考虑进一步开展后续研究。
局限性
- 本研究为I期剂量探索研究,样本量较小(26例),疗效数据需在更大规模研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To estimate the maximally tolerated dose (MTD) and describe toxicities associated with lenvatinib and weekly paclitaxel in patients with recurrent endometrial and platinum resistant epithelial ovarian cancer. METHODS: Using a 3 + 3 design patients were given weekly paclitaxel 80 mg/m2 IV day 1, 8, 15 and oral levantinib daily on a 28-day cycle. Lenvatinib dose levels were 8 mg, 12 mg, 16 mg, 20 mg. Toxicities were recorded using CTCAE v4.03 and response was determined with imaging after cycle 2, then every 3rd cycle, using RECIST 1.1 criteria. RESULTS: 26 patients were enrolled; 19 with ovarian cancer (14 high grade serous, 1 low grade serous, 2 clear cell, 1 endometrioid, and 1 carcinosarcoma), and 7 with endometrial cancer (3 serous, and 4 endometrioid). The MTD was established at lenvatinib 16 mg and weekly paclitaxel 80 mg/m2. Toxicities (all grades) occurring in ≥25% of patients included anemia, neutropenia, lymphopenia, mucositis, nausea, diarrhea, anorexia, hypertension, fatigue, proteinuria, epistaxis, hoarseness. Twenty-three patients were evaluable for response and PFS; 15 (65%) had a partial response, 7 (30%) stable, 1 (4%) progressive disease with an objective response rate of 65%; 71% in ovarian and 50% in endometrial cancer. Median progression free survival (PFS) is 12.4 months; 14.0 months in endometrial cancer, 7.2 months in ovarian cancer; 54% had a PFS > 6 months. The median duration of response for PR patients (n = 15) was 10.9 months. CONCLUSIONS: The regimen was tolerable with manageable side effects. Encouraging activity was observed in endometrial and ovarian cancer, and warrants further development.
引用
- Backes FJ, Wei L, Chen M, et al. Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer. Gynecol Oncol. 2021. PMID: 34272090. doi:10.1016/j.ygyno.2021.06.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。